Overview Financials News + Filings Key Docs Ownership Insiders
|
|
MiNK Therapeutics, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | | | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | | | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | | | | | 103.2% | -36.1% | -309.1% | 452.6% |
| General and administrative | | | | | 23.5% | -8.8% | -74.8% | 86.9% |
| Depreciation | | | | | -0.6% | | -1.5% | 2.4% |
| EBIT | | | | | 226.7% | 145.0% | 483.9% | -439.5% |
| Pre-tax income | | | | | -59.4% | 154.6% | 546.2% | -562.0% |
| Income taxes | | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | | | | | -59.4% | 154.6% | 546.2% | -562.0% |
|